March 31st, 2026 5 min read For people whove struggled for years with excessive weight, GLP-1s are a paradigm shift
2022 R&D Spend: In 2022, Sanofi spent 6.71 billion ($7.05 billion USD) on R&D, a 17.81 percent increase from the 5.69 billion ($6.73 billion USD) Sanofi spent on R&D in 2021
The possible association between GLP-1 RAs and thyroid cancer warrants ongoing surveillance, but the absolute risk remains low
Remember, meeting certain criteria, like having a specific BMI or existing health conditions, is usually key
Always consult your healthcare provider to determine the most appropriate treatment for your condition.
However, a recent study did not support this finding but rather attributed the increased risk of insulin resistance to the concomitant presence of metabolic dysfunctionassociated steatotic liver disease (MASLD) (81)